NCT03378934View on ClinicalTrials.gov

Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention

PHASE4RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 26, 2018

Primary Completion Date

June 30, 2025

Study Completion Date

August 31, 2025

Conditions
Coronary Artery DiseasePercutaneous Coronary Intervention
Interventions
DRUG

Berberine

Berberine 200 mg twice daily for 4±1 weeks (Stage 1); then, 300 mg twice daily for 4±1 weeks (Stage 2); then, 400 mg twice daily for 4 weeks (Stage 3).

DRUG

Standard treatment

Standard treatment for 12±1 weeks.

DRUG

Aspirin

Aspirin 100 mg once daily for 12±1 weeks.

DRUG

Clopidogrel

Clopidogrel 75 mg once daily for 12±1 weeks.

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER